

# List of Abbreviations

<b>Acronym</b>	<b>Definition</b>
ACN	Acetonitrile
ACVA	azobis-cyan valeric acid
AFM	atomic force microscope
AIBN	2,2-azobisisobutyronitrile
AMPD	azobis methyl propionamide dihydrochloride
ANDA	Abbreviated New Drug Application
ANVISA	Agência Nacional de Vigilância Sanitária
API	Active Pharmaceutical Ingredient
AR & D	Analytical Research & Development
ASEAN	Association of South East Asian Nations
ASTM	American Society for Testing and Materials
ATR	Attenuated total reflectance
BA	Bioavailability
BE	Bioequivalence
BLA	Biologics License Application
CAPA	Corrective and Preventive Actions
CBE	Changes Being Effected
CBE-30	Changes Being Effected – 30 Days
CBER	Center for Biologics Evaluation and Research
CDER	Center for Drug Evaluation & Research
CDRH	Center for Devices and Radiological Health
CE	Capillary Electrophoresis
CE	Conformité Européenne
CFR	Code of Federal Regulations
cGMPs	current Good Manufacturing Practices
CHMP	Committee for Medicinal Products for Human Use
CI	confidence interval
CMC	Chemistry, Manufacturing & Controls
COA	Certificate of Analysis
CQA	Critical Quality Attribute
CR	Child Resistant
CRH	Critical relative Humidity

CRO	Contract Research Organization
CRT	Controlled Room Temperature
CTD	Common Technical Document
DES	Drug eluting stent
DMF	Device Master File
DMSO	Dimethylsulfoxide
DPI	Dry powder inhaler
DRIFTS	Diffuse reflectance infrared Fourier-transform spectroscopy
DSC	Differential scanning calorimetry
ECMWF	European Centre for Medium-Range Weather Forecasts
EEC	European Economic Community
ELISA	Enzyme-linked immunosorbent assay
EMA	European Medicines Agency
EMRO	World Health Organization (WHO) Regional Office for the Eastern Mediterranean
EP	European Pharmacopoeia
ERH	Equilibrium relative humidity
EU	European Union
FAR	Field Alert Report
FDA	Food and Drug Administration
FID	Flame Ionization Detector
FMEA	Failure Mode and Effects Analysis
FT-IR	Fourier Transform Infrared spectroscopy
GC	Gas Chromatography
GCC	Cooperation Council for the Arab States of the Gulf
GHTF	Global Harmonization Task Force
HDPE	High density polyethylene
HMG	3-hydroxy-3-methyl-glutaryl
HPLC	High performance liquid chromatography
ICH	International Conference on Harmonization
IEF	Isoelectric focusing
IFPMA	International Federation of Pharmaceutical Manufacturers & Associations
IFU	Instructions for use
IGC	Inverse gas chromatography
IND	Investigational New Drug
IP	Intellectual property
IPAC-RS	International Pharmaceutical Aerosol Consortium on Regulation and Science
IQ	Installation qualification
IRA	Interim Revision Announcement
ISO	International Organization for Standardization
ITFG	Inhalation Technology Focus Group
J-NDA	(Japan) New Drug Application
JPMA	Japan Pharmaceutical Manufacturers Association

KBr	Potassium bromide
LC/MS-MS	Liquid chromatography/Mass spectroscopy-Mass spectroscopy
LC-NMR	Liquid chromatography/Nuclear magnetic resonance
LC-PDA	Liquid chromatography/photo-diode array
LIMS	Laboratory information management system
LOD	Limit of Detection
LOD	Loss on Drying
LOQ	Limit of Quantitation
LVP	Large Volume Parenteral
MDD	Medical Devices Directive
MDI	Metered Dose Inhaler
MHLW	(Japan) Ministry of Health, Labour and Welfare
MKT	Mean Kinetic Temperature
MPD	Medicinal Products Directive
MRI	Magnetic Resonance Imaging
MS/ELSD/CAD	Mass Spectrometry/Evaporative Light Scattering Detector/Charged Aerosol Detector
MVA	Multi-variate analysis
MVTR	Moisture vapor transmission rate
NCEs	New Chemical Entities
NDA	New Drug Application
NIR	Near-infrared (IR)
NIST	National Institute of Standards and Technology
NMP	<i>N</i> -methylpyrrolidone
NMR	Nuclear Magnetic Resonance
OCP	Office of Combination Products
OINDP	Orally Inhaled and Nasal Drug Products
OOS	Out of Specification
OOT	Out-of-Trend
OQ	Operational qualification
OTC	Over-the-counter
P & ID	
PAC-ATLS	Post-Approval Changes – Analytical Testing Lab Site
PAL	(Japan) Pharmaceutical Affairs Law
PAS	Prior Approval Supplement
PAT	Process analytical technology
PCA	Principal component analysis
PDA	Photo-diode array
Ph. Eur.	European Pharmacopoeia
PLS	Partial least squares
PMDA	(Japan) Pharmaceutical and Medical Devices Agency
PMOA	Primary Mode of Action
PQ	Performance qualification
PQRI	Product Quality Research Institute
PTI	Parametric tolerance interval

PVC	Polyvinyl chloride
QA	Quality Assurance
QA/QC	Quality Assurance/Quality Control
QbD	Quality by Design
QL	Quantitation Limit
RA	Regulatory Affairs
rDNA	Recombinant DNA
RFD	Request for Designation
RH	Relative humidity
RMS	Root-mean-square
RS	Reference Standards
RSD	Relative standard deviation
SADC	Southern African Development Community
SBI	Significant Body of Information
SDS-PAGE	Sodium dodecyl sulfate polyacrylamide gel electrophoresis
SEC	Size-exclusion chromatography
SE-HPLC	Size-exclusion HPLC
SEP	Standard error of prediction
SFC	Supercritical fluid chromatography
SIM	Stability-indicating method
SOP	Standard Operating Procedure
SUPAC	Scale Up and Post-Approval Changes
TGA	Thermogravimetric analysis
TLC	Thin layer chromatography
UHPLC	Ultra High Performance Liquid Chromatography
UPLC	Ultra Performance Liquid Chromatography
USP	United States Pharmacopeia
USP/NF	United States Pharmacopeia/National Formulary
UTC	Coordinated Universal Time
UV	Ultraviolet
WFI	Water for Injection
WHO	World Health Organization
XRPD	X-ray powder diffraction
Y <sub>P</sub> <sub>D</sub>	Yearly mean partial water vapor pressure

# Index

## A

- Accelerating aging
  - combining relative humidity and temperature, 130–131
  - humidity, 129–130
  - pharmaceutical product shelf-life and, 124–131
  - precision with, 133
  - temperature effects, 124–129
    - heterogeneous systems, 127–129
    - physical stability, 129
    - simple chemical degradation, 124–127
- Accuracy
  - for analytical method validation, 165–166
  - definition, 165–166
- Active pharmaceutical ingredient (API), 2
  - chemical and solid-state forms, 243
  - degradation in pharmaceutical systems, *see* Pharmaceutical product shelf-life
  - ERH effect on stability, 130–131
  - stability requirements for changes, 103–104
  - stability studies, 11–12
  - temperature effect on stability, 130–131
- Addition of new strength, stability requirements, 102
- Aggregation, 358
- American Society for Testing and Materials (ASTM) Raman standard material, 236
- Amorphous form
  - drug substance physical stability, 246–249
  - formation, 247
  - hygroscopicity, 248
  - techniques for physical properties and stability, 249
- Analytical method, changes stability requirements, 107–108
- Analytical method transfer
  - acceptance criteria, 179
  - assay, 179–180
  - dissolution, 181–182
  - examples, 184–186
  - experimental design, 179–182
  - impurities and degradation products, 180–181
  - issues, 183
  - process, 176–183
  - protocol, 177–179
  - report, 182
- Analytical method validation
  - aspects of, 164–165
  - ICH guideline on, 164
  - method transfer process, 176–183
  - regulatory requirements, 184
  - re-validation, 174
  - with stage of development, 174–175
  - technology transfer, 176
  - in USP, 164–165
  - validation parameters, 165–173
    - accuracy, 165–166
    - detection and quantitation limits, 171
    - linearity, 167–168
    - precision, 166–167
    - range, 168–169
    - robustness, 171–173
    - specificity, 169–171
    - system suitability criteria, 173
- Appearance
  - and pharmaceutical product shelf-life, 120
  - testing for stability program, 202–207
- Approved NDA (ANDA), 94, 184, 280
  - changes in, *see* Changes to ANDA
- Arabian Peninsula, stability guidelines, 71, 75–76
- Arithmetic mean temperature and MKT, 36
- ASEAN Guideline on Stability Testing of Drug Product, 340

- ASEAN member countries  
 climatic data for, 56–57  
 stability guidelines, 53–58, 340  
   development of, 55, 57–58  
   Indonesia, 53–54  
   Philippines, 54  
 stability requirements, 5  
 testing conditions for, 55, 57
- Aspirin tablets, chemical degradation, 242
- Assay, 334–335
- Atomic force microscopy (AFM), 248–249
- B**
- Beer-Lambert law, 217
- Beer's Law, 217
- Bioanalytical techniques, for biologics stability testing, 363
- Bioassays, 355, 363
- Biologics  
 ICH Q5C guideline, 360–366  
   drug product stability, 361  
   drug substance stability, 360–361  
   matrixing and bracketing, 361–362  
   stability protocols, 363–366  
   stability tests, 362–363  
 process changes stability, 367  
 products, 353–354  
 proteins degradation pathways, 356–358  
 and small molecules, 355–356  
 specification setting, 366–367  
 stability considerations, 358–360
- Biologics License Application (BLA), 360–361
- Bracketing, 315–316  
 for biologics, 361–362  
 for drug-device combination products, 344  
 guidelines, 24
- Brazil  
 climatic data, 61–62  
 partial vapour pressure fluctuations in, 59  
 stability guidelines for, 58–63  
 stability testing requirements, 62  
 temperature fluctuations in, 59
- Brazilian National Health Authorities, 60
- Bulk stability studies, 33
- C**
- Capillary electrophoresis (CE), 155
- Capsules stability program, 204–205, 215–216  
 brittleness testing, 204–205  
 physical tests, 215–216
- Caribbean islands, stability guidelines in, 86–87, 90
- Center for Biologics Evaluation and Research (CBER), 325, 341
- Center for Devices and Radiological Health (CDRH) guidance, 324–325, 341–342
- Center for Drug Evaluation and Research (CDER), 325, 334, 341–342
- Central America  
 stability guidelines in, 84–86, 89–90  
 testing conditions for, 85–86, 89
- Certificate of Analysis (COA), 176, 178, 180
- CGMP stability requirements, 4, 15–17  
 expiration dating, 17  
 reserve samples, 16–17  
 stability testing program, 15–16
- Change in critical excipient, stability requirements, 100, 102
- Changes Being Effected (CBE), 95, 97, 184
- Changes to ANDA  
 comparability protocols, 111  
 evaluation of, 94–96  
 major changes, 97  
 minor changes, 96  
 moderate changes, 96–97  
 multiple changes, 109–110  
 pharmaceutical development considerations, 111–112  
 stability requirements for, 99–108  
   analytical method changes, 107–108  
   changes to API, 103–104  
   expiration date changes, 106–107  
   formulation changes, 100, 102  
   manufacturing changes, 99–101  
   packaging changes, 102–103  
   specifications method changes, 107–108  
   stability protocol changes, 104–106  
 that affects multiple products, 109–110  
 types and  
   filing requirements, 96–97  
   global filing requirements, 97–99  
   type I variation, 97–98  
   type II variation, 98–99
- Chemical form of API, 243
- Chemical stability, and pharmaceutical product shelf-life, 116–118, 342
- Chemistry and Manufacturing Controls (CMC) dossier  
 drug product and substance stability sections in, 282  
 requirement of stability reports, 280–282
- Chemometrics, 224, 228–234, 236–237
- China

- climatic data for, 64
  - partial vapour pressure fluctuations in, 65
  - stability guidelines for, 63–67
  - temperature fluctuations in, 64–65
  - Chinese Pharmacopoeia 2005*, 65
  - Chiral detectors, 150
  - Climatic data, 47–48
    - ASEAN member countries, 56–57
    - Brazil, 61–62
    - China, 64
    - equations for, 48–50
      - dewpoints, 48
      - Mean kinetic temperature, 49–50
      - partial water vapour pressure, 48–49
      - relative humidity, 49
      - saturation water vapour pressure, 48–49
      - temperature, 48
    - India, 67–69
    - Middle East, 78–79
    - Northern and Eastern Africa, 72–74
    - SADC, 86
    - South Africa, 84
    - Southern Asia, 80
  - Climatic zones
    - concept, 44–45
    - criteria to classify, 45
  - China
    - climatic data for, 64
    - partial vapour pressure fluctuations in, 65
    - stability guidelines for, 63–66
    - temperature fluctuations in, 64–65
    - Chinese Pharmacopoeia 2005*, 65
  - Chiral detectors, 150
  - Climatic data, 47–48
    - ASEAN member countries, 56–57
    - Brazil, 61–62
    - China, 64
    - equations for, 48–50
      - dewpoints, 48
      - Mean kinetic temperature, 49–50
      - partial water vapour pressure, 48–49
      - relative humidity, 49
      - saturation water vapour pressure, 48–49
      - temperature, 48
    - India, 67–69
    - Middle East, 78–79
    - Northern and Eastern Africa, 72–74
    - SADC, 86
    - South Africa, 84
    - Southern Asia, 80
  - Climatic zones
    - concept, 44–45
    - criteria to classify, 44–45
  - for Eastern Mediterranean region, 81–82
  - of India by WHO criteria, 70
  - Koppen–Geiger classification, 45
  - by Schumacher and Grimm, 44
  - and testing conditions, 44
  - WHO classification, 45
  - Clinical materials expiry dating, 277
  - Clinical supplies of drug, stability studies to support, 12–13
  - Code of Federal Regulations, 324
  - Color testing, for stability program, 203
  - Combination drugs, and stress testing, 151
  - Combination of drug and device, *see* Drug-device combination products
  - Commercial stability commitment, for drug-device combination products, 348
  - Committee for Medicinal Products for Human Use (CHMP), 23, 27, 325
  - Common Technical Document (CTD), 165, 281
  - Confocal Raman spectroscopy, 227
  - Congo, partial vapour pressure fluctuations in, 85
  - Contaminants testing, for stability program, 203
  - Content uniformity testing, for stability program, 216–217
  - Corrective actions and preventive actions (CAPA), 293, 308
  - Creams testing, 206
  - Critical quality and performance attributes (CQAs), 112
  - Critical relative humidity (CRH), 127–128
  - Current Good Manufacturing Practices (cGMPs), 164
  - Cypher™, 342
- ## D
- Deamidation, 357–358
  - Decision tree, for registration of drug-device combination products, 330–332
  - Deliquescence process, 127
  - Delivered-dose uniformity, in nasal spray and inhaled products, 335–337
  - Delivery volume testing, for stability program, 213–214
  - Denaturation, 357
  - Density testing, for stability program, 218
  - Design Qualification (DQ), 289
  - Detection and quantitation limits, for analytical method validation, 171

- Development of SOPs, 304–309
  - sample
    - destruction and disposition, 308–309
    - inventory maintenance, 309
    - pulling, 306–307
    - testing turnaround, 307
  - study
    - activation, 306
    - amendment, 308
    - cancellation, 308
    - completion, 308
    - deviation, 308
    - set-up, 305–306
- Dewpoints, equations for, 48
- Differential scanning calorimetry (DSC), 244, 249–250
- Diffuse reflectance infrared Fourier-transform spectroscopy (DRIFTS), 245, 249
- Disintegration testing, for stability program, 217
- Disordered forms formation, 247
- Dissolution testing, for stability program, 202, 219–221
- Dose content uniformity, in nasal spray and inhaled products, 333–334, 335
- Drug-carrier systems, 248
- Drug development process
  - clinical phase, 2–3
  - purpose of phases, 2–3
  - registration phase, 3–4
  - stability role in, 10–11
  - toxicological phase, 2
- Drug-device combination products
  - additional considerations, 328
  - bracketing, 345
  - commercial stability commitment, 348
  - decision tree for registration of, 330–332
  - definition, 324
  - drug eluting stents, 342–343
  - guidance and regulatory framework
    - available, 324–328
  - implantable delivery systems, 343
  - leachables studies, 344–345
  - matrixing, 345
  - nasal spray and inhaled products, 333–340
    - assay, 334–335
    - classification, 333
    - delivered-dose uniformity, 335–337
    - dose content uniformity, 335–337
    - in-use testing, 339–340
    - moisture, 338
    - particle–droplet size and fine particle mass, 337–338
    - particulate matter-foreign particles in MDIs and DPIs, 338–339
    - stability considerations-requirements, 340
    - stability tests for, 334
    - storage conditions, 339
  - pen-injectors, 340–342
  - stability strategies for, 328–333
  - storage orientation, 345–346
  - temperature cycling, 346
  - transdermal products, 343–344
  - transportation studies, 346–347
- Drug eluting stents (DES), 342–343
- Drug instability with time
  - extrapolation and, 121–123
  - heterogeneous systems, 123
  - and lag time behavior, 123–124
  - shelf-life of, 121–124
- Drug products
  - protocol, 364–366
  - stability for biologics, 360–361
  - time and temperature schedule for, 365
  - See also* Drug substance
- Drug registration, stability studies to support, 13
- Drug substance
  - acid and base hydrolysis, 148–149
  - oxidation, 149
  - physical stability, 251–258
    - amorphous form, 246–249
    - chemical and solid-state forms, 243
    - hydrate, 245–246
    - liquid dosage forms, 255–258
    - polymorphism, 244–245
    - powder mixtures and blends, 253–254
    - solid dosage forms, 253–255
    - and solid-state characteristics, 242–251
    - solid-state physical change, 249–251
    - solutions, 255–256
    - suspensions, 256–258
    - tablets, 254–255
  - protocol, 363–366
  - reaction mechanism and degradation pathway, 149
  - stability for biologics, 360–361
  - stress testing
    - parameters, 146
    - recommendation, 29
  - time and temperature schedule for, 364
- Drug substance solid-state characteristics
  - amorphous form, 246–249
  - chemical and solid-state forms, 243
  - hydrate, 245–246



- and physical stability, 242–251
  - polymorphism, 244–245
  - solid-state physical change, 249–251
  - Dry powder inhalers (DPIs), 252, 333–340, 345
  - particulate matter-foreign particles in, 338–339
  - registration stability protocol for, 340
  - stability tests for, 334
- E**
- Eastern Mediterranean region (EMR)
    - stability guidelines, 70–82
      - Arabian Peninsula, 71, 75–76
      - climatic zones for, 81–82
      - long-term stability testing conditions for, 81–82
      - Middle East, 71, 78–79
      - Northern and Eastern Africa, 71–74
      - Saudi Arabia, 71, 77
      - Southern Asia, 71, 80
  - Electrophoretic gel method, 355
  - Emulsion, 252
  - Enzyme-linked immunosorbent assay (ELISA), 355
  - Equilibrium relative humidity (ERH), 130–131
  - European Agency for the Evaluation of Medicines (EMA), 94, 325, 327, 333
  - European Centre for Medium-Range Weather Forecasts (ECMWF), 48
  - Eutonic mixture, 127
  - Excipient compatibility, 12
  - Excursions, studies to support, 34
  - Expert Working Group (EWG), 23
  - Expiration dating
    - changes stability requirements, 106–107
    - of clinical materials, 277
    - commercial specifications and extension of, 277
    - stability program for, 17
- F**
- Failure Mode and Effects Analysis (FMEA), 347
  - FDA draft guidance status, 25–26
  - Federal Register, United States, 23, 27
  - Field Alert Report (FAR), 100, 274
  - Fill volume and delivery volume testing, for stability program, 213–214
  - Fine particle mass, in nasal spray and inhaled products, 337–338
  - Finished product forms testing
    - capsules, 204–205
    - creams, 206
    - lotions, 206
    - lyophilized products, 206
    - non-sterile solutions, 205–206
    - parenteral, 205–206
    - pressurized delivery systems, 206–207
    - reconstitution time, 206
    - for stability program, 204–207
    - tablets, 204
  - Flowability testing, for stability program, 203
  - Forced degradation studies
    - acid and base hydrolysis of drug substance in solution, 148, 150
    - experimental approach to, 146–149
    - FDA, EMA guidelines and pharmacopeias, 144–145
    - ICH guidelines, 142–143
    - reaction mechanism and degradation pathway, 149
    - for specificity, 169–171
    - for stability-indicating method, 141–151
    - stress testing
      - conditions, 146–149
      - protocol for, 146
    - timeline for conducting, 141, 146
  - Formulation
    - changes
      - addition of new strength, 102
      - change in critical excipient, 100, 102
      - product reformulation, 100
      - stability requirements, 100, 102
    - development
      - stability studies to support, 12–13
  - Fourier transform infrared spectroscopy (FTIR), 207, 224, 226, 249
  - testing for stability program, 207–208
  - Freeze–thaw testing, 34, 359, 365–366
  - Friability testing, 215
  - FT-NIR instrument, 226
  - FT-Raman, 249
- G**
- Gliadel™ Wafer, 343
  - Global Harmonization Task Force (GHTF), 324
  - Good Manufacturing Practice (GMP)
    - activity, 362
    - requirements for stability reports, 277–278
  - Guidance and regulatory framework, available for drug-device combination products, 324–328

**H**

- Hard gelatin capsules, 252
- Hardness testing, 215–216
- Health Canada, 94, 333
- Heterogeneous systems, and drug instability, 123
- HPLC stability-indicating method
  - development
    - approach, 154–155
    - process, 151–158
    - report, 158
  - mass balance, 157–158
  - on-column degradation and rearrangement, 157
  - optimization, 155–156
  - peak purity, 155
  - preliminary requirements, 152–154
    - functional group effects, 153–154
    - physico-chemical properties of drugs, 153
    - related structures, 154
    - samples of drug, 153
  - sample stability, 157
  - scope of, 152–153
  - stability-indicating chromatography conditions, 154–155
- Humidity
  - chemical stability and, 129–130
  - and pharmaceutical product shelf-life, 129–130
- Humidity-controlled thermogravimetric analysis (TGA), 245, 250
- Hydrate drug substance
  - control during drying process, 246
  - physical stability, 245–246

**I**

- ICH Expert Working Group, 51
- ICH Q1A(R2) guidelines, 4, 22–39, 51, 94, 164, 325, 360
  - container closure system, 30
  - data evaluation, 33
  - light exposure study, 28
  - selection of batches, 29
  - specifications, 30
  - stability commitment, 32–33
  - storage conditions, 31–32
  - stress testing, 27–29
    - drug product, 28–29
    - drug substance, 27–29
  - summary of, 22–32
  - testing frequency, 30–31
- ICH Q6B guideline, 362, 367

- ICH Q5E guideline, 367
- ICH stability guidelines, 4, 22–39, 51
  - applicable to stability testing, 22–39
  - bracketing and matrixing, 25
  - development of, 22–25
  - evaluation of stability data, 25
  - history of, 22–23
  - ICH Q1A(R2), 22–33
  - parent guideline, 24
  - photostability testing, 24
  - stability testing for new dosage forms, 24–25
  - stability testing of biotech products, 25
  - steps in, 23
- Identification threshold, definition of, 116
- Immunoblot method, 355
- Implantable delivery systems, for drug-device combination products, 343
- India
  - climatic data for, 67–69
  - climatic zone according to WHO criteria, 70
  - long-term stability test conditions calculations, 67–70
  - physical and climatic conditions, 67
  - stability guidelines for, 67–70
- Indonesia, stability guidelines for, 53–54
- Inhaled products, 333–340
  - assay, 334
  - classification, 333
  - delivered-dose uniformity, 335–337
  - dose content uniformity, 335–337
  - FDA guideline for, 339
  - in-use testing, 339–340
  - moisture, 338
  - particle–droplet size and fine particle mass, 337–338
  - particulate matter-foreign particles in MDIs and DPIs, 338–339
  - stability considerations-requirements, 340
  - stability tests for, 334
  - storage conditions, 339
  - See also* Nasal sprays
- In-house training, 309
- In-process testing studies, 33
- Installation Qualification (IQ), 289–290
- International Conference on Harmonization (ICH) guidelines, *see* ICH stability guidelines
- International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), 55

- International Organization for Standardization (ISO), 328
- International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS), 337–339, 345
- Intravenous (IV) solutions, particulate matter in, 218
- Intrinsic dissolution, 249
- In-use testing  
for nasal spray and inhaled products, 339–340  
studies, 34
- Inverse gas chromatography (IGC), 249
- Investigational New Drug (IND) guidance, 2, 175
- IR absorbance spectroscopy, 224
- Isoelectric focusing (IEF), 355
- Isothermal microcalorimetry, 249
- J**
- Japanese Pharmaceutical Affairs Law (PAL), 328
- Japan Pharmaceutical Manufacturers Association (JPMA), 328
- K**
- Karl Fischer testing, 202, 239
- Karl Fischer titration  
blanking of vessel, 209–210  
handling cautions, 210  
moisture testing by, 208–210, 246  
percent recovery standard, 210  
sample analysis, 210  
standardization, 210
- KIT Drug and Medical Device Certification, 327
- L**
- Laboratory controls, 17, 310
- Laboratory information management system (LIMS), 278, 280, 305, 230
- Laboratory records, for stability program, 18
- Lag time behavior, and drug instability, 123–124
- Large volume parenterals (LVPs), 252
- Leachables studies, for drug-device combination products, 344–345
- Limit of Detection, 171
- Limit of Quantitation (LOQ), 171, 268–269
- Linearity, 237  
for analytical method validation, 164–165  
definition, 165
- Liquid drug product, physical stability, 255–258
- Liquids, FTIR spectroscopic testing, 208
- Liquid sample cells, FTIR spectroscopic testing, 208
- Loss on drying (LOD), moisture testing by, 208–209, 246
- Lotions testing, 206
- Low solubility drugs, and stress testing, 150
- Lyophilization cycles, 359
- Lyophilized products, 206, 358
- M**
- Manufacturing changes, stability requirements, 99–101
- Marketing Authorization Application (MAA), 3
- Matrixing, 316–319  
for biologics, 362  
design, 315  
for drug-device combination products, 346–347  
guidelines, 24
- Mean kinetic temperature (MKT)  
arithmetic mean temperature and, 36  
calculation, 35–36  
concept, 34–40  
definition, 34  
equations for, 48–50  
limitations, 39–40  
temperature  
excursions, 39  
fluctuations, 36–39
- Medical Device Certification, 327
- Medical Device Directive (MDD), 326–327
- Medical Product Directive (MPD), 326
- Melting point testing, for stability program, 218
- Metered dose inhalers (MDIs), 333, 338–339, 345  
particulate matter-foreign particles in, 338–339  
stability tests for, 336
- Method transfer  
acceptance criteria for, 179  
of dissolution, 181–182  
example, 184–186  
experimental design, 179–182  
issues, 183  
process, 176–183  
protocol, 177–179  
report, 182–183
- Method validation  
documentation, 175  
with stage of development, 174–175

- Microbial growth, and pharmaceutical product shelf-life, 120
- Microbiological stability, 242
- Microscopic image analysis, 249
- Middle East
  - climatic data for, 78–79
  - stability guidelines for, 71, 78–79
- Ministry of Health, Labour and Welfare (MHLW), Japan, 23, 27
- Modulated differential scanning calorimetry (MDSC), 249
- Moisture testing
  - in nasal spray and inhaled products, 338
  - for stability program, 208–210
- Monographs
  - standards development process, 191–192
  - validation requirements for submission, 192
- Monte-Carlo method, 133
- Multiple products changes, 109–110
- Multivariate analysis (MVA), 224–225, 228–233, 236–237
  
- N**
- Nasal sprays, 252, 333–340
  - assay, 334
  - classification, 333
  - delivered-dose uniformity, 335–337
  - dose content uniformity, 335–337
  - FDA guideline for, 339
  - in-use testing, 339–340
  - moisture, 338
  - particle–droplet size and fine particle mass, 337–338
  - particulate matter-foreign particles in MDIs and DPIs, 338–339
  - stability considerations-requirements, 340
  - stability tests for, 334
  - storage conditions, 339
- National Institute of Standards and Technology (NIST)
  - standard reference materials for NIR, 235
- Near infrared (NIR) spectroscopy, 225–227, 233–236, 239, 245–246, 249, 254
  - method validation, 236–239
  - NIST standard reference materials for, 235
- New Chemical Entities (NCEs), 2, 4, 264
- New Drug Application (NDA), 94, 165
  - See also* Approved NDA (ANDA)
- New drug products
  - degradant allowed for, 117
  - stability studies to develop, 10–11
- New drug substance
  - degradation product in, 277
  - specified impurity in, 276
- New employee training, 310
- Non-chromatographic methods for stability program
  - appearance testing, 202–207
  - content uniformity, 216–217
  - density, 218
  - disintegration, 217
  - dissolution, 219–221
  - fill volume and delivery volume, 213–214
  - FTIR spectroscopic testing, 207–208
  - melting point, 218
  - moisture testing, 208–210
  - particulate matter, 218
  - pH, 212–213
  - residual solvents analysis, 211–212
  - specific gravity, 218
  - tablet and capsule physical tests, 215–216
  - UV/Vis spectroscopy, 217
  - weight variation, 213–214
- Non-sterile solutions testing, 205–206
- Northern and Eastern Africa
  - climatic data for, 72–74
  - stability guidelines for, 71–74
  
- O**
- Office of Combination Products (OCP), 325
- Operation Qualification (OQ), 289, 290–291
- Oral solution, 252
- Oral suspension, 252
- Ostwald ripening, 119, 257
- Out-of-Specification (OOS) investigations, 5, 9, 180, 186, 263, 269–275
  - at accelerated conditions, 274
  - checklist, 271
  - confirmation of result, 274
  - form, 273
  - full-scale investigation, 272–274
  - identification of results, 265
  - laboratory investigation, 270–272
    - at long-term storage conditions, 275
  - outlier testing, 274
  - retesting, 272–274
  - trending results, 275
- Out-of-Trend (OOT) investigations, 5
  - by-time-point method, 268
  - evaluation for stability, 263, 265–268
  - graphical evaluation, 266–267
  - regression control chart method, 267
  - slope control chart method, 268
  - statistical evaluation, 267
- Outside training, 310

- Over-The-Counter (OTC) drugs, 16  
Oxidation, 357
- P**
- Packaged product, stability prediction in, 133–134
- Packaging changes, stability requirements for, 102–103
- Paclitaxel, 342
- Panama  
  stability guidelines in, 84–86, 89–90  
  testing conditions for, 85–86, 89
- Parametric tolerance interval (PTI) test, 337
- Parenterals  
  particulate matter for stability program, 218  
  particulate matter in, 218  
  testing, 205–206
- Parent ICH stability guidelines (ICH Q1A), 24
- Partial water vapour pressure ( $P_D$ )  
  equations for, 48–49  
  fluctuations  
    in Brazil, 59  
    in China, 64  
    in Congo, 85  
    in Philippines, 54  
    in Saudi Arabia, 77  
    for South Africa, 83
- Particle–droplet size, in nasal spray and inhaled products, 337–338
- Particulate matter  
  and foreign particles in MDIs and DPIs, 338–339  
  for stability program, 218
- Peak purity analysis, 155
- Pen injectors, 340–342
- Peptide digest mapping, 355
- Performance Qualification (PQ), 289, 291–293
- PH  
  calibration, 213  
  measurement, 213  
  for stability program, 212–213
- Pharmaceutical and Medical Devices Agency (PMDA), 327
- Pharmaceutical development, considerations and changes to ANDA, 111–112
- Pharmaceutical dosage forms, physical attributes in, 252
- Pharmaceutical products  
  stability testing program for, 15–16  
  testing and release for distribution, 17–18
- Pharmaceutical product shelf-life  
  accelerating aging and, 124–131  
  combining relative humidity and temperature, 130–131  
  humidity, 129–130  
  temperature effects, 124–129
- appearance and, 118–120  
chemical stability and, 116–118  
drug instability with time and, 121–124  
  extrapolation, 121–123  
  heterogeneous systems, 123  
  lag time behavior, 123–124  
factors determining, 116–121  
microbial growth and, 120  
photochemical degradation and, 121  
physical stability and, 118  
precision and, 132–133  
  with accelerated aging, 133  
  extrapolation with time, 132–133  
prediction of stability, 133–134  
temperature effects  
  heterogeneous systems, 127–129  
  physical stability, 129  
  simple chemical degradation, 124–127
- Pharmacopeial Forum (PF), 191
- Pharmacopeial harmonization efforts, 359
- Pharmacopeia of the United States of America-National Formulary (USPA-NF)*  
  glossary of terms, 190–191  
  history, 190  
  monographs  
    standards development process, 191–192  
    validation requirements for submission, 192  
  reference standards  
    qualification process flow, 193  
    in stability testing, 192–193  
  requirements for stability, 189–199  
  stability requirements, 189–199  
    case study, 198–199  
    compendial procedures, 195–198  
    compendial tests, 197  
    General Information Chapter 1150  
      Pharmaceutical Stability, 195  
    information on general notices and requirements, 194–195  
    parenteral, 198–199  
    solid oral dosage form, 197–198  
  stability requirements in, 189–199
- Philippines  
  partial vapour pressure fluctuations in, 55  
  stability guidelines for, 54–55  
  temperature fluctuations in, 54

- Photochemical degradation, and  
pharmaceutical product  
shelf-life, 121
- Photostability  
studies, 365
- Photo-stability chambers, 295–300  
calibration, 299–300  
monitoring and alarms, 300  
options, 295–298  
preventative maintenance and back-up, 300  
qualification, 298–299
- Physical stability, 242  
of drug products, 251–258  
liquid dosage forms, 255–258  
powder mixtures and blends, 253–254  
solid dosage forms, 253–255  
solutions, 255–256  
suspensions, 256–258  
tablets, 254–255  
of drug substance, 242–251  
amorphous form, 246–249  
chemical and solid-state forms, 243  
hydrate, 245–246  
polymorphism, 244–245  
and solid-state characteristics, 242–251  
solid-state physical change, 249–251  
and pharmaceutical product shelf-life, 118  
temperature effects on, 129
- Polarized light microscopy (PLM), 249
- Polymorphism and  
physical stability of drug, 244–245  
stress testing, 150
- Post-Approval Changes-Analytical Testing  
Lab Site (PAC-ATLS), 184
- Powder inhalers (DPIs), 333, 338–339  
particulate matter-foreign particles in,  
338–339
- Powders, 252  
mixtures and blends drug product, 253–254  
physical stability, 253–254  
testing for stability program, 203
- Pre-approval inspection (PAI), 184
- Precision, 237  
with accelerated aging, 133  
for analytical method validation, 166–167  
definition, 166  
extrapolation with time, 132–133  
and pharmaceutical product shelf-life,  
132–133
- Pre-clinical supplies of drug, stability studies  
to support, 12–13
- Pressurized delivery systems testing, 206–207
- Primary Mode of Action (PMOA), 325, 342
- Prior approval supplement (PAS), 95, 106
- Process analytical technology (PAT), 112,  
223–224, 245–246, 254
- Product Quality Research Institute  
(PQRI), 345
- Product reformulation, stability  
requirements, 100
- Prolifeprosan 20 with carmustine implant, 343
- Proposed changes, evaluation of, 94–96
- Proteins  
degradation pathways, 356–358  
problems with stability of, 357
- Pure Food and Drug Act, 190
- Q**
- Qualification threshold, definition of, 116
- Quality assurance (QA), 94–95, 112
- Quality by Design (QbD) concepts, 112,  
156–157, 171, 224, 241–242
- Quality Risk Management guidance, 112
- Quantitative analysis  
and equipment, 224–228  
equipment qualification, 234–236  
method validation, 236–239  
MVA and chemometrics, 228–234  
vibrational spectroscopy methods for,  
223–239
- R**
- Raman scattering, 226
- Raman spectroscopy, 225–228, 236, 239, 254  
method validation, 236–239
- Range, 239  
for analytical method validation, 168–169  
definition, 168
- Reach-in stability chambers, 286–287
- Reconstitution time testing, 206
- Regional stability guidelines, 53–90  
in ASEAN member countries, 53–58  
Indonesia, 53–54  
Philippines, 54–55  
testing conditions for, 55  
in Brazil, 58–63  
in Caribbean islands, 86–87, 90  
in Central America, 84–86, 89–90  
in China, 63–67  
in Eastern Mediterranean region, 70–82  
Arabian Peninsula, 71, 75–76  
climatic zones for, 81–82  
long-term stability testing conditions  
for, 81–82  
Middle East, 71, 78–79  
Northern and Eastern Africa, 71–74  
Saudi Arabia, 71, 77

- Southern Asia, 71, 80
  - testing condition humidity, 77, 79, 81
  - testing condition temperature, 74, 76–77
- global stability testing protocols, 87, 90
- in India, 67–70
- in Panama, 84–86, 89–90
- in South Africa, 82–84
- in South American countries, 63–64
- in Southern Africa, 82–85
- Registration, of drug-device combination products, 330–332
- Regulatory framework, available for drug-device combination products, 324–328
- Relative humidity (RH), equations for, 49
- Reporting threshold, definition of, 116
- Reserve samples, for stability program, 16–17
- Residual solvents analysis
  - instrumentation, 211
  - miscibility of solvents, 212
  - in pharmaceutical API and excipients, 211–212
  - for stability program, 211–212
  - standard preparation, 211–212
- Ritonavir, 244
- Robustness, for analytical method validation, 171–173, 239
  
- S**
- Salt plates, FTIR spectroscopic testing, 208
- Sample inventory form, 307
- Saturation water vapour pressure ( $P_s$ ), equations for, 48–49
- Saudi Arabia
  - partial vapour pressure fluctuations, 77
  - stability guidelines for, 71, 77
  - temperature fluctuations, 77
- Scale Up and Post-Approval Changes (SUPAC) guidance, 94–95, 184
- Scan electron microscopy (SEM), 249
- Semi-permeable container, conditions for, 32
- Semisolids, 252
- Shelf-life of pharmaceutical product, *see* Pharmaceutical product shelf-life
- Short-term heat–stress studies, 359
- Significant Body of Information (SBI), 99
- Significant changes, definitions of, 31
- Single-needle technique, for stability program, 214
- Sirolimus, 342
- Size-exclusion chromatography (SEC), 158
- Size-exclusion HPLC (SE-HPLC), 355
- Small-angle X-ray scattering (SAXS), 249
- Small volume parenterals (SVPs), 252
- Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), 355
- Soft gelatin capsules, 252
- Solid drug product, physical stability, 253–255
- Solids, FTIR spectroscopic testing, 207
- Solid-state
  - API, 243
  - characteristics of drug substance and physical stability, 242–251
  - NMR, 249
  - physical change mechanism and stress stability, 249–251
- Solutions drug product, physical stability, 255–256
- South Africa
  - climatic data for, 84
  - partial vapour pressure fluctuations, 83
  - stability guidelines for, 82–83
  - temperature fluctuations in, 83
- South American countries
  - long-term testing conditions for, 64
  - stability guidelines for, 63–64
- Southern Africa, for stability guidelines, 82–85
- Southern Asia
  - climatic data for, 80
  - stability guidelines for, 71, 80
- Specification
  - setting for biologics, 366–367
- Specifications
  - commercial specifications, 277
  - expiry dating of clinical materials, 277
  - and extension of expiration dating, 277
  - refinement using stability studies, 275–277
  - and stability data, 275–277
  - stability requirements for changes, 107–108
- Specific gravity testing, for stability program, 218
- Specificity, 238
  - for analytical method validation, 169–171
  - definition, 169
- Stability
  - for biologics process changes, 367
  - chronological order of activities, 320
  - compendial tests for, 197
  - concept, 242
  - data evaluation, 263–282
    - by-time-point method, 268
    - flow diagram, 264
    - graphical OOT evaluation, 266–267
    - guidelines, 25

Stability (*cont.*)

- importance, 269
  - regression control chart method, 267
  - reviewing impurity assay results, 268–269
  - slope control chart method, 268
  - specifications setting and, 275–277
  - statistical evaluation of OOT, 267 and trending, 264–265
  - data sheet elements, 278–279
  - indicating chromatography conditions, 154–155
  - methodologies, 5
  - OOS results, 265, 269–275
  - OOT results, 263, 265–268
  - practices, 5, 43–90
  - prediction in packaged product, 133–134
  - protocols for biologics, 363–366
  - regulations, 4
  - reports, 277–282
    - anatomy, 279–280
    - GMP requirements, 277–278
    - requirement for CMC, 280–282
    - stability data sheet elements, 278–279
  - requirements
    - case study, 198–199
    - compendial procedures for stability, 195–198
    - General Information Chapter 1150 Pharmaceutical Stability, 195
    - information on general notices and requirements, 194
    - parenteral, 198–199
    - solid oral dosage form, 198
  - requirements for nasal spray and inhaled products, 340
  - results evaluation, 265–269
  - specifications and data, 275–277
    - commercial specifications and extension of expiration dating, 277
    - expiry dating of clinical materials, 277
    - refinement using stability studies, 275–277
- Stability chambers
- calibration, 293–294
  - excursions, 301–302
  - monitoring and alarm system, 295
  - photostability, 295–300
    - calibration, 299–300
    - chamber, 297
    - monitoring and alarms, 300
    - options, 295–298
    - preventative maintenance and back-up, 300
    - qualification, 298–299
  - preventative maintenance and chamber back-up, 294
  - qualification, 289–293
    - installation qualification, 289–290
    - operation qualification, 290–291
    - performance qualification, 291–293
    - requalification, 293
  - reach-in chambers, 286–287
  - size, 286–287
  - specifications, 288
  - walk-in chambers, 286–287
- Stability guidelines
- Arabian Peninsula, 71, 75–76
  - ASEAN member countries, 53–58
  - Brazil, 58–63
  - Caribbean islands, 86–87, 90
  - Central America, 84–86, 89–90
  - China, 63–67
  - Eastern Mediterranean region, 70–82
  - India, 67–70
  - Indonesia, 53–54
  - Middle East, 71, 78–79
  - Northern and Eastern Africa, 71–74
  - Panama, 84–86, 89–90
  - Philippines, 54–55
  - Saudi Arabia, 71, 77
  - South Africa, 82–83
  - South American countries, 63–64
  - Southern Africa, 82–85
  - Southern Asia, 71, 80
  - of WHO, 5, 22, 51–53
- Stability-indicating method (SIM)
- development and validation, 139–159
  - FDA, EMEA guidelines and pharmacopeia, 144–145
  - forced degradation studies, 141–151
    - acid and base hydrolysis of drug substance in solution, 148–149, 150
    - experimental approach to, 141–149
    - guidelines and pharmacopeia, 144–145
    - ICH guidelines, 142–143
    - protocol for stress testing, 146
    - reaction mechanism and degradation pathway, 149
    - stress testing conditions, 146–149
    - timeline for conducting, 141, 146
  - HPLC method development, 151–158
  - ICH guidelines, 142–143



- stress testing
  - combination drugs, 151
  - conditions, 146–149
  - degradants characterization, 151
  - in forced degradation studies, 146–149
  - low solubility drugs, 150
  - polymorphism, 150
  - protocol for, 146
  - special considerations in, 150–151
  - stereochemical stability, 150
- Stability Operating Procedures (SOPs), 15, 165, 177–178, 182, 264, 266, 271–273, 279, 282, 288, 289–294, 300, 302, 304–309
- annual product review, 319
- bracketing, 314, 315–316
- development of, 304–309
- matrixing, 314, 316–319
- sample
  - destruction and disposition, 308–309
  - inventory maintenance, 309
  - pulling, 306–307
  - testing turnaround, 307
- stability protocols, 310–314
  - contents, 310–311
  - establishment, 310
  - standard, 311–314
- structure, 304
- study
  - activation, 306
  - amendment, 308
  - cancellation, 308
  - completion, 308
  - deviation, 308
  - set-up, 305–306
- training program, 307–308
  - establishing laboratory controls, 310
  - in-house training, 309
  - new employee training, 310
  - outside training, 310
  - requirements, 309
  - types, 309–310
- Stability program
  - cGMP requirements, 15
  - critical regulatory requirements, 9–19
  - expiration dating, 17
  - laboratory controls, 17
  - laboratory records, 18
  - non-chromatographic methods, 202–219
    - appearance testing, 202–207
    - content uniformity, 216–217
    - density, 218
    - disintegration, 217
    - dissolution, 219–221
    - fill volume and delivery volume, 213–214
    - FTIR spectroscopic testing, 207–208
    - melting point, 218
    - moisture testing, 208–210
    - particulate matter in parenterals and intravenous (IV) solutions, 218
    - pH, 212–213
    - residual solvents analysis, 211–212
    - specific gravity, 218
    - tablet and capsule physical tests, 215–216
    - UV/Vis spectroscopy, 217
    - weight variation, 213–214
  - for pharmaceutical products, 15–16
  - reserve samples, 16–17
  - testing and release for distribution, 17–18
- Stability protocols, 310–314
  - contents, 310–311
  - establishment, 310–311
  - stability requirements for changes in, 104–106
  - standard, 311–314
- Stability requirements
  - analytical method changes, 107–108
  - for changes to ANDA, 99–108
  - changes to API, 103–104
  - expiration date changes, 106–107
  - formulation changes, 100–102
  - manufacturing changes, 99–100
  - packaging changes, 102–103
  - specifications and analytical method changes, 107–108
  - stability protocol changes, 104–106
- Stability studies
  - active pharmaceutical ingredient, 11–12
  - pull windows for, 306
  - purpose, 140–141
  - role in drug development process, 10–11
  - special studies, 33–34
    - bulk stability, 33
    - Freeze-Thaw studies, 34
    - in-process testing, 33
    - in-use testing, 34
    - to support excursions, 34
    - thermal studies, 34
  - to support
    - drug registration, 13
    - formulation development, 12
    - marketed products, 13

- Stability studies (*cont.*)  
 pre-clinical and clinical supplies of drug, 12–13  
 production and use of drug, 12–13  
 types, 11–13
- Stability testing  
 of biotech products, 25  
 guidelines, 22–25  
 ICH guidelines applicable to, 21–40  
 for new dosage forms, 24–26  
 probability of failure, 45–47  
 additional safety margins, 47  
 built-in safety margins, 46  
 risk factors, 45–46  
 variability in loading and resistance, 47  
 program for pharmaceutical products, 15–16  
 scientific principles of, 13–15
- Stability tests  
 for biologics, 362–363  
 for nasal spray and inhaled products, 334–336
- Stereochemical stability, and stress testing, 150
- Stokes' Law, 256–257
- Storage conditions, for nasal spray and inhaled products, 339
- Storage orientation, for drug-device combination products, 345–346
- Stress stability  
 and solid-state physical change mechanism, 249–251  
 testing of drug substances, 250
- Stress testing  
 combination drugs, 151  
 conditions, 146–149  
 degradants characterization, 151  
 in forced degradation studies, 146–149  
 low solubility drugs, 150  
 parameters for drug substance and drug product, 147  
 polymorphism, 150  
 protocol for, 146  
 special considerations in, 150–151  
 for stability-indicating method, 146–151  
 stereochemical stability, 150
- Supercritical fluid chromatography (SFC), 155
- Suppositories, 252
- Surface plasmon resonance, 355
- Suspensions drug, physical stability, 256–258
- System suitability criteria, for analytical method validation, 173
- T**
- Tablets, 252  
 drug physical stability, 254–255  
 friability, 215  
 hardness, 215–216  
 tests for stability program, 204, 215–216
- Tanzania, temperature fluctuations in, 84
- Taxus<sup>TM</sup> stent, 342
- Technology transfer, and analytical method validation, 176
- Temperature  
 effects on pharmaceutical product shelf-life, 124–129  
 equations for, 48  
 excursions and MKT, 39  
 fluctuations  
 in Brazil, 59–60  
 in China, 63–65  
 and MKT, 36–39  
 in Philippines, 54  
 in Saudi Arabia, 77  
 for South Africa, 83  
 Tanzania, 84
- Temperature cycling, for drug-device combination products, 346
- Terahertz Pulsed Spectroscopy, 245, 249
- Testing conditions  
 for Central America and Panama, 84–86, 89  
 humidity, 77, 79, 81  
 temperature, 74, 76–77
- Thermal dehydration process mechanism, 245
- Thermal microscopy, 249
- Thermal studies, 34
- Thin-layer chromatography (TLC), 155, 158
- Training program  
 establishing laboratory controls, 310  
 in-house training, 309  
 new employee training, 310  
 outside training, 310  
 requirements, 309  
 under SOPs, 309  
 types, 309–310
- Transdermal patches, 252
- Transdermal products, 343–344
- Transportation studies, for drug-device combination products, 346–347
- Triboelectric property, 249
- Two-needle technique, for stability program, 214
- Type I variations, 97–98
- Type II variations, 98–99

**U**

UV/Vis spectroscopy, for stability program, 217

**V**

Validation of analytical method, *see* Analytical method validation

Viadur<sup>TM</sup> leuprolide acetate implant, 343

Vibrational spectroscopy

and equipment, 224–228

equipment qualification, 234–236

design qualification, 234

installation qualification, 234

operational qualification, 235

performance qualification, 234–236

methods for quantitative analysis, 223–239

method validation, 236–239

MVA and chemometrics, 228–234

**W**

Walk-in stability chambers, 286–287

Water for injection (WFI), volume of, 206

Water vapor sorption, 249

Weight variation testing, for stability program, 213–214

WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations, 51

WHO Expert Committee on Specifications for Pharmaceutical Preparations, 51

World Health Organization (WHO), 94

classification of climatic zones, 45

stability guidelines, 4, 22, 51–53

current status, 52–53

development of, 51

harmonization efforts, 51–52

**X**

X-ray powder diffraction (XRPD), 244–246, 249